Medicis to restate financial results
This article was originally published in Scrip
Medicis Pharmaceuticalshas suspended its financial guidance for the rest of the year and has said that its financial statements for the annual, transition and quarterly periods from 2003 will probably need to be restated. The restatement has been caused by necessary modifications in the company's interpretation of the generally accepted accounting principles relating to sales return reserve calculations, Medicis says. Although it said that the restatement was not expected to affect its cash flow or cash balance for any of the affected periods, the company's share price plunged by nearly 16% on September 24th. Sales of Medicis's lead product Solodyn (minocycline HCl) have been hit by the weak US economy and the product will soon face generic competition.
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.